Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$102.80 USD
-2.21 (-2.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $102.78 -0.02 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 1 - 20 ( 720 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2Q24 Results; Four New Commercial-Stage Assets Added to the Growing Royalty Roster in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Ohtuvayre Approved; Ligand''s Milestone and Royalty Outlook Expands
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
1Q24 Results; the Checkbook Is Atctive; 10 Assets Added Since Mid-23 With Significant Agenus Deal Added Yesterday
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2023 Results; Solid Footing Points to Strong Year of Royalty and BD Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
ZELSUVMI Approved; Commercial Launch Expected in 2H24 But Focus on Outlicense by Ligand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J